Development

Feliza Mirasol is the science editor for 

Articles

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.

Takeda Gets Approval in Japan for Entyvio Subcutaneous Injection 

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

Catalent Licenses Bhami Research Laboratory Technology for Biologics Formulation Development

Meg Rivers is the former senior editor for 

While a variety of innovations have already impacted the drug delivery landscape, improving sustainability and having the ability to make smaller volumes of drug products still require work.

Advances in Drug Delivery and Areas for Improvement

The company has officially opened a local brand office in South Korean to support its existing business in the region.

Vetter Expands in Asia-Pacific

Adeline Siew is science editor for BioPharm International.

Siliconization is a key process step in the manufacturing of prefilled syringe systems.

Delivering Biologics in Prefilled Syringes

The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.

Lilly to Invest $72 Million for Insulin Manufacturing Upgrade

Nemera is now authorized to handle, assemble, sterilize, and store pharmaceutical drugs and medicinal products for autoinjector combination products at its facility in Neuenburg, Germany.

Nemera Receives Drug Manufacturing Authorization for its Autoinjector Facility

Shell Ip, PhD, is a technical marketing specialist at Precision Nanosystems.

R. James Taylor, PhD, is CEO and co-founder at Precision Nanosystems.

Ilya Captain, PhD, is a field application scientist at Precision Nanosystems.

Dave Reichert is a technical marketing writer at Precision Nanosystems.

This review examines how microfluidics has been used in the formulation, preclinical, and clinical development of gene-delivery nanoparticles.

Accelerating Genetic Medicine R&D Using Microfluidics

Genentech gets priority review for its application seeking a new indication for its anti-cancer drug, Gazyva (obinutuzumab), in treating follicular lymphoma.

FDA Grants Priority Review to Genentech’s Anti-Cancer Drug

The US Patent and Trademark Office issued three new patents that extend protection for Alexion’s rare-disease drug, Soliris, for an additional 10 years.


Formulation and Drug Delivery, Liquids